Wall Street analysts forecast that Evogene Ltd (NYSE:EVGN) will announce ($0.19) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Evogene’s earnings. Evogene posted earnings per share of ($0.20) during the same quarter last year, which would indicate a positive year-over-year growth rate of 5%. The company is expected to issue its next quarterly earnings report before the market opens on Monday, November 20th.

On average, analysts expect that Evogene will report full year earnings of ($0.74) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.44) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Evogene.

Evogene (NYSE:EVGN) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.05). The firm had revenue of $1.18 million for the quarter. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%.

Several hedge funds and other institutional investors have recently bought and sold shares of EVGN. Jane Street Group LLC boosted its position in Evogene by 71.1% during the 1st quarter. Jane Street Group LLC now owns 50,129 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 20,837 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Evogene by 53.4% during the 1st quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock valued at $4,079,000 after acquiring an additional 85,425 shares in the last quarter. Vanguard Group Inc. boosted its position in Evogene by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 436,225 shares of the biotechnology company’s stock valued at $2,443,000 after acquiring an additional 17,391 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Evogene by 59.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock valued at $3,246,000 after acquiring an additional 226,778 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in Evogene by 142.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 680,000 shares of the biotechnology company’s stock valued at $3,414,000 after acquiring an additional 400,000 shares in the last quarter. 29.88% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/04/0-19-eps-expected-for-evogene-ltd-evgn-this-quarter.html.

Shares of Evogene (EVGN) traded up $0.21 during trading on Friday, reaching $4.22. 4,270 shares of the company’s stock were exchanged, compared to its average volume of 34,494. Evogene has a 52 week low of $3.60 and a 52 week high of $6.12.

Evogene Company Profile

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Get a free copy of the Zacks research report on Evogene (EVGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.